| Title | Author(s) | Year | View Count |
 | Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase | Du, J; Zhou, Y; Su, X; Yu, JJ; Khan, S; Jiang, H; Kim, J; Woo, J; Kim, JH; Choi, BH; He, B; Chen, W; Zhang, S; Cerione, RA; Auwerx, J; Hao, Q; Lin, H | 2011 | 153 |
 | A new concept of continental construction in the Central Asian Orogenic Belt: (Compared to actualistic examples from the Western Pacific) | Safonova, I; Seltmann, E; Kröner, A; Gladkochub, D; Schulmann, K; Xiao, W; Kim, J; Komiya, T; Sun, M | 2011 | 130 |
| An all-in-one adhesive does not etch beyond hybrid layers | Kim, J; Mai, S; Carrilho, MR; Yiu, CKY; Pashley, DH; Tay, FR | 2010 | 204 |
| Quantum size effects on the work function of metallic thin film nanostructures | Kim, J; Qin, S; Yao, W; Niu, Q; Chou, MY; Shih, CK | 2010 | 520 |
| In vitro remineralization of severely compromised bonded dentin | Mai, S; Kim, YK; Kim, J; Yiu, CKY; Ling, J; Pashley, DH; Tay, FR | 2010 | 137 |
| Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease | Yuen, MF; Han, KH; Um, SH; Yoon, SK; Kim, HR; Kim, J; Kim, CR; Lai, CL | 2010 | 62 |
 | Pyongyang | Roberts, PM; Kim, J | 2010 | 10 |
| Clock synchronization in wireless sensor networks: An overview | Rhee, IK; Lee, J; Kim, J; Serpedin, E; Wu, YC | 2009 | 459 |
| Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice | Yuen, MF; Lee, SH; Kang, HM; Chung, RK; Kim, J; Ngai, V; Lai, CL | 2009 | 451 |
| Are there long-run implications of analyst coverage for IPOs? | Chan, K; Bradley, D; Kim, J; Singh, A | 2008 | 188 |
| The IPO Derby: Are there consistent losers and winners on this track? | Chan, K; Cooney, J; Kim, J; Singh, A | 2008 | 161 |
| An MTT-based method for quantification of periodontal ligament cell viability | Kim, E; Jeon, IS; Kim, JW; Kim, J; Jung, HS; Lee, SJ | 2007 | 37 |
| A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B | Yuen, MF; Kim, J; Kim, CR; Ngai, V; Yuen, JCH; Min, C; Kang, HM; Shin, BS; Yoo, SD; Lai, CL | 2006 | 204 |
| Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV | Lai, CL; Han, KH; Yoon, SK; Um, SH; Yuen, MF; Kim, HS; Kim, HR; Chung, HC; Kim, CR; Hsyu, P; Averett, D; Worland, S; Kim, J | 2006 | 200 |
| Molecular phylogenetic relationships of Asiatic black bear (Ursus thibetanus) populations in East Asia and its conservation implications | Min, M; Hong, Y; Park, H; Kim, Y; Kim, Y; Han, S; Smith, GJ; Renzhu, P; Hwang, M; Myslenkov, A; Voloshina, IV; Kim, C; Kim, J; Lee, H | 2006 | 177 |
| Interim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection | Yuen, RMF; Kim, J; Wong, DKH; Ngai, WS; Yuen, JCH; Lai, CL | 2004 | 146 |
| Interim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection. | Yuen, RMF; Kim, J; Wong, DKH; Ngai, WS; Yuen, JCH; Lai, CL | 2004 | 132 |
| Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection. | Yuen, RMF; Kim, J; Averett, D; Wong, DKH; Kim, CR; Kerr, B; Ngai, WS; Yuen, JCH; Lai, CL | 2004 | 198 |
| A phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in patients with chronic hepatitis B infection | Yuen, RMF; Kim, J; Wong, DKH; Ngai, WS; Yuen, JCH; Lai, CL | 2003 | 152 |
| Quantile inference with multivariate failure time data | Yin, G; Cai, J; Kim, J | 2003 | 99 |
|
